PTEN Research
Paul Elvin is an experienced professional in the field of translational medicine and science. Currently serving as the Director of Translational Medicine at PTEN Research since July 2019, Paul also contributes as a Consultant Translational Scientist at Oncognition from November 2015 to the present. Previously, from November 2015 to January 2023, Paul held the position of Chief Translational Science Officer at Aptus Clinical Ltd. Paul's extensive career began at AstraZeneca R&D, where Paul worked as a Principal Scientist for nearly 27 years, from October 1988 to November 2015.
This person is not in the org chart
This person is not in any teams
PTEN Research
PTEN Research is a UK-registered charity. We fund and facilitate research that will lead to new and better treatment for PHTS, a rare genetic condition which currently has no health authority approved therapies. We do this by funding PHTS research projects and bringing together a global network of PHTS focused experts and other key partners. PTEN hamartoma tumour syndrome (PHTS) is a rare genetic disease caused by mutations in the PTEN gene. An individual with a PTEN mutation may be diagnosed as having Cowden Syndrome (CS), Bannayan-Riley-Ruvalcaba Syndrome (BRRS), or Autism Spectrum Disorder (ASD) associated with macrocephaly (large head). Together this spectrum of conditions is known as PHTS. Registered charity number: 1173589